Business ❯ Pharmaceutical Industry

Vaccine Development

Moderna COVID-19 Vaccines Market Impact Pfizer Regulatory Affairs Market Reactions Corporate Governance mRNA Technology AstraZeneca Moderna Inc. Technology Transfer Valneva Partnerships Clinical Trials Investment Market Authorization Johnson & Johnson BioNTech Combination Vaccines Legal Accountability Market Demand Novavax Market Dynamics Public Trust Market Regulation Regulatory Policy Innovation in Healthcare Patent Disputes Covid-19 Vaccines Investment Trends COVID-19 Response Intellectual Property Rights Product Liability Biontech/Pfizer Contracts Corporate Communication Marketing Practices Market Competition COVID-19 Vaccine Manufacturers Emergency Use Authorization Funding Research Funding Market Trends Funding Impact Funding Projects Funding Allocations Investment in Health Drug Manufacturers Market Performance Regulatory Challenges Corporate Influence Funding Policies Regulatory Agencies Operation Warp Speed Bavarian Nordic Risk Management Product Safety Regulatory Approval Research and Development Stock Market Investment Risks Market Access Takeda Research Collaborations Laboratory Operations

Florida Sues Pfizer and CEO Over COVID-19 Vaccine Marketing

The state alleges the company hid safety risks and misled consumers and is asking for fines, profit returns and a court order to stop the conduct.

Moderna Begins Phase III Trial of mRNA Bird Flu Vaccine in UK and US

Pfizer and BioNTech Halt U.S. COVID Vaccine Trial for 50–64-Year-Olds Over Slow Enrollment

FDA Reverses Course To Review Moderna’s mRNA Flu Shot Under Split Pathway

FDA Refuses to File Moderna’s mRNA Flu Vaccine Application Over Trial Comparator

Valneva Pulls U.S. Filings for Chikungunya Vaccine as FDA Halts Trials Over Safety Review

Moderna Scraps CMV Vaccine Program After Phase 3 Failure

FDA Grants Full Approval to Moderna’s Pediatric COVID-19 Vaccine for At-Risk Children

Moderna’s mRNA-1010 Flu Vaccine Outperforms Standard Shot and Advances Toward Approval

FDA Grants Limited Approval to Novavax’s COVID-19 Vaccine